Variants of vesicular stomatitis virus (VSV) have been thoroughly investigated for their oncolytic potential.7–9 VSV belongs to the family of Rhabdoviridae10 and its rapid replication cycle and wide host cell range make for a promising therapeutic agent.11 Tumour selectivity of VSV is predominantly based on defects in the antiviral defence capabilities of malignant cells,8 a feature commonly seen in many human malignancies.12,13 VSV-GP is a chimeric VSV variant with its glycoprotein (G) replaced by the lymphocytic choriomeningitis virus (LCMV) derived glycoprotein (GP). Here, ART4 is linked to neoplasm.